Frank E. Blondino
22Patents
11h-index
12Co-inventors
72Inventor score
Filing activity: Mar 23, 1994 → Jun 24, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5492688A | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent | Human Necessities | 76 | Expired |
| US8939943B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 61 | Active |
| US9173999B2 | Devices and methods for delivering medicaments from a multi-chamber container | Emerging Cross-Sectional Technologies | 56 | Active |
| US6004537A | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol | Performing Operations; Transporting | 42 | Expired |
| US8627816B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 42 | Active |
| US5508023A | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant | Human Necessities | 40 | Expired |
| US6451285B2 | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant | Human Necessities | 21 | Expired |
| US9022022B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 21 | Active |
| US7501113B2 | Aerosol formulations and aerosol delivery of buprenorphine | Human Necessities | 20 | Expired |
| US6290930A | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide | Human Necessities | 14 | Expired |
| US7410635B2 | Aerosol formulations and aerosol delivery of scopolamine | Human Necessities | 12 | Expired |
| US9517307B2 | Devices and methods for delivering opioid antagonists including formulations for naloxone | Emerging Cross-Sectional Technologies | 9 | Active |
| US9474869B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 9 | Active |
| US10143792B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 8 | Active |
| US9814838B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 6 | Active |
| US10183116B2 | Devices and methods for delivering medicaments from a multi-chamber container | Emerging Cross-Sectional Technologies | 5 | Active |
| US10322239B2 | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | Human Necessities | 4 | Active |
| US10695495B2 | Devices and methods for delivering a lyophilized medicament | Emerging Cross-Sectional Technologies | 4 | Active |
| US9522235B2 | Devices and methods for delivering medicaments from a multi-chamber container | Physics | 2 | Active |
| US10220158B2 | Devices and methods for delivering opioid antagonists including formulations for naloxone | Emerging Cross-Sectional Technologies | 1 | Active |
| US12005236B2 | Devices and methods for delivering a lyophilized medicament | Emerging Cross-Sectional Technologies | 1 | Active |
| US10226583B2 | Devices and methods for delivering medicaments from a multi-chamber container | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.